Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
CureApp’s Smoking Cessation App under Review as Medical Device; Reimbursement Price Will Be Key: President
The medical IT startup CureApp has submitted its nicotine dependence treatment app, which is designed to increase the effectiveness of treatment through behavioral modification, for approval as a medical device in Japan, President Kota Satake revealed on July 5. “We’re…
To read the full story
Related Article
- Japan’s 1st Therapeutic App Now Available: CureApp
December 2, 2020
- Japan’s 1st Therapeutic App OK’ed for Health Coverage, Due for Release on Dec. 1
November 12, 2020
- Japan to Set New Technical Fee for CureApp’s Quit Smoking App
November 10, 2020
- Approval Now in Hand, CureApp Looks at Collaborations with Drug Makers to Push Therapeutic Apps
September 29, 2020
- Japan Approves CureApp’s Smoking Cessation Apps
August 24, 2020
- Japan Likely to OK CureApp’s Smoking Cessation App in July
June 23, 2020
- CureApp to File Hypertension Treatment App as Early as 2021, PIII Trial Now Underway
February 3, 2020
- CureApp to Begin Clinical Trial of Japan’s First “Treatment App” in October
August 24, 2017
BUSINESS
- Eisai to Raise 50 Billion Yen via Bond Issue for R&D, Licensing
June 5, 2026
- Japan Market for Fertility, Contraception, Female Disorders Put at 228.5 Billion Yen by FY2035
June 5, 2026
- Toho, DHL Partner on Healthcare Logistics Platform
June 5, 2026
- Keytruda Maintains Lead as Japan’s Top-Selling Drug for 32nd Month: Encise
June 5, 2026
- Boehringer’s Japan Pharma Sales Up for 7th Straight Year, 10-Plus Launches Eyed by 2030
June 4, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…